IXICO PLC (IXI)

Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

11.00p

Buy

11.50p

arrow-down-0.615p (-5.12%)

Prices updated at 30 May 2025, 13:09 BST
| Prices minimum 15 mins delay
|
Prices in GBX
IXICO PLC is engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies.
FTSE All-Share
arrow-up0.76%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Mark Robert Warne
CEO
Mr. Bram Goorden
Most recent earnings
30 Sep 2024
Fiscal year end
30 Sep 2024
Employees
74
Head office
15 Long Lane
London
United Kingdom
EC1A 9PN
mobile
+44 2037637499
letter
companysecretary@ixico.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Mark Robert Warne
Non-Executive Director, Chairman
-
Dr. Dipti Mahendra Amin
Non-Executive Director
-
Ms. Katherine Jane Rogers
Non-Executive Director
-
Mr. Grant Robert Nash
Executive Director, Chief Financial Officer and Company Secretary
-
Mr. Bram Goorden
Executive Director, Chief Executive Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Octopus Investments Limited5,827,027
Maven Renovar VCT Ord4,442,857
Unicorn Asset Management Ltd3,586,000
Unicorn AIM VCT Series 3 ORD3,586,000
Octopus AIM VCT ORD3,427,027

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
04 Dec 2024Purchase
04 Dec 2024Sale
28 Oct 2024Purchase
28 Oct 2024Purchase
28 Oct 2024Purchase
28 Oct 2024Purchase
28 Oct 2024Purchase
28 Oct 2024Purchase
28 Oct 2024Purchase
10 Oct 2024Purchase
09 Oct 2024Purchase
09 Oct 2024Exercise of Option
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.